These findings suggest QSYQ as a potential alternative treatment for patients presenting with ischemic heart diseases like acute angina pectoris with modulation of energy metabolism as one of the major underlying mechanisms, to which AS-IV and Rb1 are the main contributors. The gene discussed is RB1; the disease is coronary artery disorder.